Australia’s premier life science investment event, AusBioInvest 2023, kicks off in Melbourne with keynotes from international investment leaders and pitch-for-investment presentations from leading biotech executives.
Australia’s biggest week is officially underway, with AusBioInvest 2023 kicking off today in Melbourne to an audience of investors and life science executives.
AusBiotech 2023 features an industry-led programme with thought-provoking keynote and panel sessions of leading investors and business leaders, in addition to the 26 Australian biotech companies, spanning early- to late-stage, that are actively seeking investors or partners to support their funding and co-development.
Held at the Parky Hyatt in Melbourne, AusBioInvest will today welcome 280 delegates representing Australia’s leading life science companies and Australian and global investors representing venture capital firms, private equity firms, high net worth individuals, research analysts and brokers, industry executives and major global stakeholders.
The programme features thought-provoking keynote and panel sessions with leading investors and business leaders, including US-based Jennifer Nason, Global Chairman, Investment Banking, J.P. Morgan, who will provide an update on global capital market trends, conditions and themes and what it means for Australian biotechs; and Kanishka Pothula, Partner, Nextech, who will participate in a fireside on considerations US investors make when evaluating a deal, with a focus on non-specialist investors; while Ajita Tynan, Manager, Listed Company Services, Australian Securities Exchange, will provide an update on the public markets in Australia.
In addition, AusBioInvest features presentations from 26 private and listed Australian biotech companies, that are actively seeking investors or partners to support their funding and co-development.
Presenting companies include: Arovella Therapeutics (ASX:ALA), Avecho Biotechnology (ASX:AVE), BiomeBank, Carina Biotech, Celosia Therapeutics, Cyban, Dimerix (ASX:DXB), EBR Systems (ASX:EBR), Encapsolutions, ESFAM Biotech, FivepHusion, Genofax, Imagion Biosystems (ASX:IBX), Immuron Limited (ASX:IMC), InhaleRx (ASX:IRX), Invion (ASX: IVX), LBT Innovations (ASX:LBT), Microba, Noxopharm Limited (ASX:NOX), PolyActiva, Prescient Therapeutics (ASX:PTX), Respiri (ASX:RSH), Snoretox, TruScreen (ASX:TRU), Tessara Therapeutics, and Vaxxas.
AusBiotech CEO Lorraine Chiroiu says, “Access to capital remains one of the biggest opportunities for biotech companies in Australia. AusBioInvest fosters meaningful connections between the investment community and investment-seeking life sciences companies, enabling great ideas to attract risk-tolerant capital while assisting investors to connect with innovative, Australian companies that offer high-value return-on-investment.”
AusBioInvest officially marks the beginning of Australia’s ‘biggest week in biotech’, with AusBiotech’s flagship national conference, AusBiotech 2023, underway in Brisbane from 1-3 November.
AusBioInvest 2023 will open with an official welcome from the Treasurer of Victoria, the Hon. Tim Pallas MP.
AusBioInvest 2023 is proudly supported by Host State Partner the Victorian State Government.
